News

News and Press Releases
Health Care Reform | Advocacy U.S. Supreme Court Rules on the Affordable Care Act

The Cystic Fibrosis Foundation celebrates the decision issued by the United States Supreme Court in California v. Texas, ultimately protecting the Affordable Care Act. 

| 3 min read
Antibiotics | Advocacy CF Foundation Affirms Support of the Introduction of the PASTEUR Act

Proposed legislation has the potential to revitalize the global marketplace for novel antibiotics, bringing urgently needed medicines for drug-resistant infections to patients.

| 2 min read
About the CF Foundation | Our Research Approach CF Foundation Launches New Collaboration to Overcome Challenges to Developing Genetic Therapies for CF

Today, the Cystic Fibrosis Foundation announced a collaboration with Deep Science Ventures to accelerate treatments that address the underlying cause of CF for every person with the disease. The collaboration will focus on uncovering and designing new technologies to address key scientific challenges on the Path to a Cure.

| 4 min read
Research | About the CF Foundation | Clinical Trials CF Foundation Awards Up to $2M to Eloxx for Additional Support for Studies into Nonsense Mutations Therapy

Today, the Cystic Fibrosis Foundation announced a new award of up to $2 million to Eloxx Pharmaceuticals Inc. to support the global Phase 2 clinical program of ELX-02, a potential therapy to treat people with cystic fibrosis who have nonsense mutations.

| 4 min read
CFTR Modulators FDA Approves Trikafta for Children Ages 6 Through 11 With Certain Mutations

The U.S. Food and Drug Administration has approved the use of Trikafta® (elexacaftor/tezacaftor/ivacaftor) for children ages 6 through 11 who have at least one copy of the F508del mutation or certain mutations in the CFTR gene that are responsive based on lab data.

| 4 min read
Clinical Trials First-of-Its-Kind Study Uses Smartphone to Track Cystic Fibrosis in Real Life

Observational study supported by the CF Foundation will monitor real-world experience with Trikafta

| 4 min read
Research | About the CF Foundation | Our Research Approach CF Foundation Funds Three New Research Awards to Advance its Path to a Cure Initiative

New funding awards include up to $2.6M to Eloxx Pharmaceuticals to identify potential therapies for CF nonsense mutations

| 5 min read
Research | About the CF Foundation | Our Research Approach CF Foundation Invests Up to $8.4M in SpliSense for the Development of Potential Rare Mutation Therapy

Today, the Cystic Fibrosis Foundation announced that it will invest up to $8.4 million in SpliSense's Series B funding round to develop an antisense oligonucleotide therapy for people with cystic fibrosis who have splicing mutations and potentially other rare mutations.

| 4 min read
Research Molecular Analysis Identifies Key Differences in Lungs of People With Cystic Fibrosis

Researchers' catalog of airway cell types could reveal targets for future genetic therapies

| 6 min read
Advocacy | About the CF Foundation CF Foundation Responds to NIH Call for Information on Diversity and Inclusion

The Cystic Fibrosis Foundation recently submitted comments to the National Institutes of Health on improving racial equity, diversity, and inclusion in the biomedical research workforce.

| 2 min read